A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes

European Journal of Pharmacology

Volumn 495, Issue 1, 2004, Pages 17-26

  Sakamoto, Junichi ^a   Kimura, Hiroyuki ^a   Moriyama, Shinji ^a   Imoto, Hiroshi ^a   Momose, Yu ^a   Odaka, Hiroyuki ^a   Sawada, Hidekazu ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Dual agonist; Partial agonist; Peroxisome proliferator activated receptor; TAK 559

Indexed keywords

ALKANOIC ACID; IMIGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECEPTOR SUBTYPE; ROSIGLITAZONE;

ARTICLE; CONCENTRATION RESPONSE; DRUG BINDING; DRUG EFFECT; DRUG POTENCY; HUMAN; PRIORITY JOURNAL;

3T3 CELLS; ADIPOCYTES; ANIMALS; BUTYRIC ACIDS; CERCOPITHECUS AETHIOPS; COS CELLS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; HISTONE ACETYLTRANSFERASES; HUMANS; HYPOGLYCEMIC AGENTS; JAPAN; MICE; OXAZOLES; PPAR GAMMA; RNA, MESSENGER; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR AP-2; TRANSCRIPTION FACTORS; TRANSFECTION;

EID: 3042668032     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2004.05.020     Document Type: Article

References (41)

1. Berger J., Bailey P., Biswas C., Cullinan C.A., Doebber T.W., Hayes N.S., Saperstein R., Smith R.G., Leibowitz M.D. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 137:1996;4189-4195
2. Berger J., Leibowitz M.D., Doebber T.W., Elbrecht A., Zhang B., Zhou G., Biswas C., Cullinan C.A., Hayes N.S., Li Y., Tanen M., Ventre J., Wu M.S., Berger G.D., Mosley R., Marquis R., Santini C., Sahoo S.P., Tolman R.L., Smith R.G., Moller D.E. Novel Peroxisome Proliferator-activated Receptor (PPAR) and PPAR ligands produce distinct biological effects. J. Biol. Chem. 274:1999;6718-6725
3. Berger J.P., Petro A.E., Macnaul K.L., Kelly L.J., Zhang B.B., Richards K., Elbrecht A., Johnson B.A., Zhou G., Doebber T.W., Biswas C., Parikh M., Sharma N., Tanen M.R., Thompson G.M., Ventre J., Adams A.D., Mosley R., Surwit R.S., Moller D.E. Distinct properties and advantages of a novel peroxisome proliferator-activated protein selective modulator. Mol. Endocrinol. 17:2003;662-676
4. Berthou L., Duverger N., Emmanuel F., Langouet S., Auwerx J., Guillouzo A., Fruchart J.C., Rubin E., Denefle P., Staels B., Branelle D. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J. Clin. Invest. 97:1996;2408-2416
5. Deeb S.S., Fajas L., Nemoto M., Pihlajamaki J., Mykkanen L., Kuusisto J., Laakso M., Fujimoto W., Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat. Genet. 20:1998;284-287
6. DeFronzo R.A., Ferrannini E. Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 14:1991;173-194
7. 2 is a ligand for the adipocyte determination factor PPARγ Cell. 83:1995;803-812
8. Forman B.M., Chen J., Evans R.M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligand for peroxisome proliferator-activated receptors α and β Proc. Natl. Acad. Sci. U. S. A. 94:1997;4312-4317
9. Horlein A.J., Naar A.M., Heinzel T., Torchia J., Gloss B., Kurokawa R., Ryan A., Kamei Y., Soderstorm M., Glass C.K., Rosenfeld M.G. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclare receptor co-repressor. Nature. 377:1995;397-404
10. Ibrahimi A., Teboul L., Gaillard D., Amri E.Z., Ailhaud G., Young P., Cawthorne M.A., Grimaldi P.A. Evidence for a common mechanism of action for fatty acids and thiazolidinedione antidiabetic agents on gene expression in preadipose cells. Mol. Pharmacol. 46:1994;1070-10766
11. Ikeda H., Taketomi S., Sugiyama Y., Shimura Y., Sohda T., Meguro K., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant. Arzneim.-Forsch./Drug Res. 40:1990;156-162
12. Imoto H., Sugiyama Y., Kimura H., Momose Y. Studies on non-thiazolidinedione antidiabetic agents: 2. Novel oxyiminoalkanoic acid derivatives as potent glucose and lipid lowering agents. Chem. Pharm. Bull. 51:2003;138-151
13. Isseman I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature. 347:1990;645-650
14. Kletzien R.F., Clarke S.D., Ulrich R.G. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol. Pharmacol. 41:1992;393-398
15. Kubota N., Terauchi Y., Miki H., Tamemoto H., Yamauchi T., Komeda K., Satoh S., Nakano R., Ishii C., Sugiyama T., Eto K., Tsubamoto Y., Okuno A., Murakami K., Sekihara H., Hasegawa G., Naito M., Toyoshima Y., Tanaka S., Shiota K., Kitamura T., Fujita T., Ezaki O., Aizawa S., Kadowaki T. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol. Cell. 4:1999;597-609
16. Lefebvre A.M., Peinado-Onsurbe J., Leitersdorf I., Briggs M.R., Paterniti J.R., Fruchart J.C., Fievet C., Auwerx J., Staels B. Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler. Thromb. Vasc. Biol. 17:1997;1756-1764
17. Lehmann J.M., Moore L.B., Smith-Oliver T.A., Wilkison W.O., Willson T.M., Kliewer S.A. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ). J. Biol. Chem. 270:1995;12953-12956
18. Ljung B., Bamberg K., Dahllof B., Kjellstedt A., Oakes N.D., Ostling J., Svensson L., Camejo G. AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. J. Lipid Res. 43:2002;1855-1863
19. Lohray B.B., Lohray V.B., Bajji A.C., Kalchar S., Poondra R.R., Padakanti S., Chakrabarti R., Vikramadithyan R.K., Misra P., Juluri S., Mamidi N.V.S.R., Rajagopalan R. (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic Acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J. Med. Chem. 44(16):2001;2675-2678
20. Lorenzo C., Okoloise M., Williams K., Stern M.P., Haffner S.M. The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study. Diabetes Care. 26:2003;3153-3159
21. Malmendier C.L., Delcroix C. Effect of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis. 55:1985;161-169
22. Mangelsdorf D.J., Evans R.M. The RXR heterodimers and orphan receptors. Cell. 83:1995;841-850
23. Murakami K., Tobe K., Ide T., Mochizuki T., Ohashi M., Akanuma Y., Yazaki Y., Kadowaki T. A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ Diabetes. 47:1998;1841-1847
24. Oberfield J.L., Collins J.L., Holmes C.P., Goreham D.M., Cooper J.P., Cobb J.E., Lenhard J.M., Hull-Ryde E.A., Mohr C.P., Blanchard S.G., Parks D.J., Moore L.B., Lehmann J.M., Plunket K., Miller A.B., Milburn M.V., Kliewer S.A., Willson T.M. A peroxisome proliferator-activated receptor g ligand inhibits adipocyte differentiation. Proc. Natl. Acad. Sci. U. S. A. 96:1999;6102-6106
25. Oliver W.R. Jr., Shenk J.L., Snaith M.R., Russell C.S., Plunket K.D., Bodkin N.L., Lewis M.C., Winegar D.A., Sznaidman M.L., Lambert M.H., Xu H.E., Sternbach D.D., Kliewer S.A., Hansen B.C., Willson T.M. A selective peroxisome proliferator-activated receptor δ agonist promotes reverse cholesterol transport. Proc. Natl. Acad. Sci. U. S. A. 98:2001;5306-5311
26. O'Moore-Sullivan T.M., Prins J.B. Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med. J. Aust. 176:2002;381-386
27. Peters J.M., Hennuyer N., Staels B., Fruchart J.C., Fievet C., Gonzalez F.J., Auwerx J. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice. J. Biol. Chem. 272:1997;27307-27312
28. Reaven G.M. Role of insulin resistance in human disease. Diabetes. 37:1988;1595-1607
29. Sakamoto J., Kimura H., Moriyama S., Odaka H., Momose Y., Sugiyama Y., Sawada H. Activation of human peroxisome proliferator-activated receptpr (PPAR) subtypes by pioglitazone. Biochem. Biophys. Res. Commun. 278:2000;704-711
30. Sauerberg P., Pettersson I., Jeppesen L., Bury P.S., Mogensen J.P., Wassermann K., Brand C.L., Sturis J., Woldike H.F., Fleckner J., Andersen A.S., Mortensen S.B., Svensson L.A., Rasmussen H.B., Lehmann S.V., Polivka Z., Sindelar K., Panajotova V., Ynddal L., Wulff E.M. Novel tricyclic-alpha- alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. 45(4):2002;789-804
31. Schmidt A., Endo N., Rutledge S.J., Vogel R., Shinar D., Rodan G.A. Identification of a new member of the steroid hormone receptor superfamily that is activated by peroxiaome proliferator and fatty acids. Mol. Endocrinol. 6:1992;1634-1641
32. Schoonjans K., Staels B., Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid Res. 37:1996;907-925
33. Sohda T., Momose Y., Meguro K., Kawamatsu Y., Sugiyama Y., Ikeda H. Studies on antidiabetic agents. Synthesis and hypoglycemic activity of 5-[4-(pyridylalkoxy) benzyl]-2, 4-thiazolidinediones. Arzneim.-Forsch./Drug Res. 40:1990;37-42
34. Staels B., Auwerx J. Regulation of apoA-I gene expression by fibrates. Atherosclerosis. 137:1998;S19-S23. (suppl)
35. Sugiyama Y., Taketomi S., Shimura Y., Ikeda H., Fujita T. Effects of pioglitazone on glucose and lipid metabolism in Wistar fatty rats. Arzneim.-Forsch./Drug Res. 40:1990;263-267
36. Sugiyama Y., Shimura Y., Ikeda H. Effects of pioglitazone on hepatic and peripheral insulin resistance in Wistar fatty rats. Arzneim.-Forsch./Drug Res. 40:1990;436-440
37. Suzuki, M., Odaka, H., Matsumoto, M., Suzuki, N., Momose, Y., Kimura, H., Sugiyama, Y., 2004. A novel oxyiminoalkanoic acid derivative, TAK-559, improves hyperglycemia and hyperlipidemia with less body fat accumulation in insulin resistant animals (in preparation).
38. Tontonoz P., Hu E., Spiegelman B.M. Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor. Cell. 79:1994;1147-1156
39. Wang J., Hoshino T., Redner R.L., Kajigaya S., Liu J.M. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex. Proc. Natl. Acad. Sci. U. S. A. 95:1998;10860-10865
40. Willson T.M., Brown P.J., Sternbach D.D., Henke B.R. The PPARs: from orphan receptors to drug discovery. J. Med. Chem. 43:2000;527-550
41. Young P.W., Buckle D.R., Cantello B.C.C., Chapman H., Clapham J.C., Coyle P.J., Haigh D., Hindley R.M., Holder J.C., Kallender H., Latter A.J., Lawrie K.W.M., Mossakowaska D., Murphy G.J., Cox L.R., Smith S.A. Identification of high-affinity binding sites for the insulin sensitizer rosiglitazone (BRL-49653) in rodent and human adipocytes using a radioiodinated ligand for perocisomal proliferator-activated receptor γ J. Pharmacol. Exp. Ther. 284:1998;751-759